With growing interest by the Pharmaceutical industry to develop new healthcare solutions in the ophthalmic disease area, we have expanded the Ophthalmic and Retinal Disease Category of our Epiomic™ database to include Uveitis. This disease can be of infectious or autoimmune origin and is generally classified by anatomical location.
We have segmented the total eligible population by the anatomical areas of the eye, ocular hypertension and visual loss, to yield a more granular view of this disease; in turn creating over 300 sub-populations. This will be important for products looking to address a specific sub-population and in situations requiring a forecast or product valuation. The information could also create huge savings by determining representative numbers of patients for clinical trial populations which meet inclusion criteria of your study.
With some considerable variations between the different countries with this disease, it will be important for users to look across all 9 markets available to accurately assess the potential for their product.
Did you know... that 55% of the patients diagnosed with Uveitis will have it in the anterior region of the eye? Of those patients, only 10% will also have an autoimmune condition like Behçet’s disease.